Live Breaking News & Updates on Protagonist Therapeutics Daily|Page 3

Stay updated with breaking news from Protagonist therapeutics daily. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

JMP Securities Increases Protagonist Therapeutics (NASDAQ:PTGX) Price Target to $45.00

JMP Securities Increases Protagonist Therapeutics (NASDAQ:PTGX) Price Target to $45.00
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Los Angeles , United States , Zurcher Kantonalbank Zurich Cantonalbank , Asif Ali , Securities Exchange Commission , Russell Investments Group Ltd , Jpmorgan Chase Co , Protagonist Therapeutics Inc , China Universal Asset Management Co , Los Angeles Capital Management , Protagonist Therapeutics Company Profile , Protagonist Therapeutics , Get Free Report , Exchange Commission , Investments Group , Universal Asset Management , Angeles Capital Management , Kantonalbank Zurich Cantonalbank , Teacher Retirement System , Retirement System , Protagonist Therapeutics Daily ,

Head to Head Analysis: Protagonist Therapeutics (NASDAQ:PTGX) versus NovAccess Global (OTCMKTS:XSNX)

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) and NovAccess Global (OTCMKTS:XSNX – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations. Institutional & Insider Ownership 98.6% of Protagonist […] ....

United States , Chagrin Falls , Novaccess Global Inc , Protagonist Therapeutics Inc , Protagonist Therapeutics , Get Free Report , Novaccess Global , Given Protagonist Therapeutic , Access Global , Access Global Inc , Protagonist Therapeutics Daily , Nasdaq Ptgx , Stock Comparison , Stock Analysis ,

Insider Selling: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CFO Sells $30,985.74 in Stock

Insider Selling: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CFO Sells $30,985.74 in Stock
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Asif Ali , Jpmorgan Chase Co , Protagonist Therapeutics Inc , Ameritas Investment Partners Inc , Royal Bank , Tower Research Capital , China Universal Asset Management Co , Protagonist Therapeutics , Get Free Report , Universal Asset Management , Research Capital , Ameritas Investment Partners , Investment Partners , Protagonist Therapeutics Daily ,

Obermeyer Wood Investment Counsel Lllp Sells 1,726 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Obermeyer Wood Investment Counsel Lllp lowered its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 12.5% in the 4th quarter, Holdings Channel reports. The fund owned 12,066 shares of the company’s stock after selling 1,726 shares during the quarter. Obermeyer Wood Investment Counsel Lllp’s holdings in Protagonist Therapeutics were worth $277,000 as of […] ....

United States , Asif Ali , Securities Exchange Commission , China Universal Asset Management Co , Jpmorgan Chase Co , Protagonist Therapeutics Inc , Protagonist Therapeutics Company Profile , Ameritas Investment Partners Inc , Board Of Administration Florida Retirement System , Holdings Channel , Principal Financial Group Inc , Obermeyer Wood Investment Counsel Lllp , Protagonist Therapeutics , Free Report , Wood Investment Counsel Lllp , Universal Asset Management , Retirement System , Florida Retirement System , Investment Partners , Principal Financial Group , Financial Group , Get Free Report , Exchange Commission , Visit Holdingschannel , Protagonist Therapeutics Daily , Nasdaq Ptgx ,

Obermeyer Wood Investment Counsel Lllp Reduces Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Obermeyer Wood Investment Counsel Lllp lessened its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 12.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 12,066 shares of the company’s stock after selling 1,726 shares during the quarter. Obermeyer Wood Investment […] ....

Hong Kong , Williamd Waddill , Ameritas Investment Partners Inc , Jpmorgan Chase Co , Protagonist Therapeutics Inc , China Universal Asset Management Co , Securities Exchange Commission , Hong Kong Ltd , Royal Bank , Tower Research Capital , Obermeyer Wood Investment Counsel Lllp , Protagonist Therapeutics , Free Report , Wood Investment Counsel Lllp , Universal Asset Management , Research Capital , Investment Partners , Kong Ltd , Get Free Report , Director William , Exchange Commission , Protagonist Therapeutics Daily , Nasdaq Ptgx , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,